Biopharmaceutical giant AbbVie has formally accelerated its strategic push into global sports marketing by announcing a multi-year partnership with the…
Read More
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
The global landscape of hepatitis C virus (HCV) management has shifted significantly in the past decade, moving from a era…
Read MoreAbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
The landscape of hepatitis C (HCV) management has undergone a profound shift, yet a stark disconnect remains between clinical efficacy…
Read More
FDA Approval of Tavapadon (Juvmo) Validates AbbVie’s $8.7bn Cerevel Takeover and Ushers in a New Era for Parkinson’s Treatment
The United States Food and Drug Administration has officially approved tavapadon, a next-generation dopamine-based therapy developed for the management of…
Read More
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
In the global effort to eradicate hepatitis C (HCV), clinical success has frequently collided with the sobering realities of public…
Read More
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
The landscape of hepatitis C (HCV) management has undergone a radical transformation over the last decade, yet the public health…
Read More
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
The landscape of hepatitis C (HCV) management has shifted significantly with the recent regulatory approvals of AbbVie’s direct-acting antiviral therapy,…
Read More
AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Bolster Immunology Pipeline
AbbVie has announced a landmark $10.9 billion acquisition of Apogee Therapeutics, a strategic move poised to significantly fortify the biopharmaceutical…
Read More
European Commission Approves AbbVie’s Aquipta (atogepant) for Acute Migraine Treatment
AbbVie has secured a significant regulatory endorsement from the European Commission (EC) for Aquipta (atogepant), marking a pivotal expansion of…
Read More
AbbVie Secures FDA Approval for Ultra-Rare Blood Cancer Therapy, While AstraZeneca Faces Delay for Breast Cancer Drug
The U.S. Food and Drug Administration (FDA) has recently issued a significant approval for AbbVie’s antibody-drug conjugate (ADC) targeting blastic…
Read More
